NCT07483359 2026-03-19
CONV3RSION
First Hospital of China Medical University
Phase 2 Not yet recruiting
Clinical Trials
13 trialsNCT07479485 2026-03-18
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Lepu Biopharma Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07481032 2026-03-18
Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study
Nanfang Hospital, Southern Medical University
Phase NA Not yet recruiting
NCT07476651 2026-03-17
LASER
Seoul National University Hospital
Phase NA Not yet recruiting
NCT07419841 2026-03-16
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
Phase 1 Not yet recruiting
NCT07391670 2026-03-12
IMFINZI-subQ
AstraZeneca
Phase 1 Not yet recruiting
NCT07436988 2026-03-12
ReLIVE
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 1 Not yet recruiting
NCT07466225 2026-03-12
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion
Peking University
Not yet recruiting
NCT07381634 2026-03-11
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT07463248 2026-03-11
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
West China Hospital
Phase 2 Not yet recruiting
NCT07461675 2026-03-10
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
University of Geneva, Switzerland
Phase 3 Not yet recruiting
NCT07446257 2026-03-03
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase EARLY_PHASE1 Not yet recruiting
NCT07422753 2026-02-20
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting